A Study of A RSV Vaccine When Given Together With Tdap in Healthy Nonpregnant Women Aged Between 18 and 49 Years
Final Report: A Phase 2b, Placebo-Controlled, Randomized, Observer-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Respiratory Syncytial Virus (RSV) Vaccine When Administered Concomitantly With Tetanus, Diphtheria, and Acellular Pertussis Vaccine (Tdap) in Healthy Nonpregnant Women 18 Through 49 Years of Age
Category & Conditions: Vaccine-related Conditions
Medicine: PF-06928316
ClinicalTrials.gov Identifier (NCT): NCT04071158
Protocol ID: C3671004
PrintDownloadOpen Plain Language Summary Result: Click here